Wanjia (HKG:0401) expects a loss of around HK$5.8 million for the year ended March 31, down 86% from HK$40.3 million a year prior, a Thursday Hong Kong bourse filing said.
The pharmaceutical distribution company attributed the loss mainly to refunds of certain items related to hemodialysis treatment requested by a county medical security bureau in China from the firm's hemodialysis treatment centers.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.